NCT02225470 - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | Biotech Hunter

Enrollment

530

Participants

Timeline

Start Date

September 26, 2013

Primary Completion Date

September 29, 2017

Study Completion Date

June 22, 2018

Conditions

HER2-Negative Breast CancerTriple Negative Breast CancerBreast CancerCancer of BreastBreast Tumors

Interventions

DRUG

E7389 (Eribulin Mesylate)

DRUG

Vinorelbine injection

Trial Locations (35)

Unknown

04 Eisai Trial Site, Bengbu

37 Eisai Trial Site, Hefei

01 Eisai Trial Site, Beijing

03 Eisai Trial Site, Beijing

33 Eisai Trial Site, Beijing

35 Eisai Trial Site, Beijing

07 Eisai Trial Site, Fuzhou

08 Eisai Trial Site, Fuzhou

20 Eisai Trial Site, Guangzhou

36 Eisai Trial Site, Guangzhou

10 Eisai Trial Site, Nanning

12 Eisai Trial Site, Shijiazhuang

11 Eisai Trial Site, Harbin

38 Eisai Trial Site, Zhengzhou

14 Eisai Trial Site, Wuhan

15 Eisai Trial Site, Wuhan

05 Eisai Trial Site, Changsha

13 Eisai Trial Site, Changsha

34 Eisai Trial Site, Changsha

18 Eisai Trial Site, Nanjing

31 Eisai Trial Site, Nanjing

16 Eisai Trial Site, Changchun

17 Eisai Trial Site, Changchun

06 Eisai Trial Site, Dalian

19 Eisai Trial Site, Shenyang

21 Eisai Trial Site, Yinchuang

24 Eisai Trial Site, Xi'an

28 Eisai Trial Site, Xi'an

22 Eisai Trial Site, Qingdao

09 Eisai Trial Site, Shanghai

23 Eisai Trial Site, Taiyuan

26 Eisai Trial Site, Chengtu

27 Eisai Trial Site, Tianjin

30 Eisai Trial Site, Yunnan

40 Eisai Trial Site, Hangzhou

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY